.Attribute Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ advanced bosom cancer as well as active or even secure human brain metastases revealed steady intracranial task and also systemic efficiency of T-DXd.